title: Relationship between use of proton pump inhibitors and IGF system in older subjects.
abstract: OBJECTIVE
  to investigate the effects of proton pump inhibitors (PPIs) on the insulin-like-growth factor 1(IGF-1) system in the elderly.
  
  
  METHODS
  cross-sectional.
  
  
  METHODS
  InCHIANTI study.
  
  
  METHODS
  938 older subjects (536 women, 402 men, mean age 75.7±7.4 years).
  
  
  METHODS
  complete data on age, sex, BMI, liver function, medications, dietary intake, IGF-1, IGF-binding protein-1 and -3 (IGFBP-1, IGFBP-3).
  
  
  RESULTS
  Participants were categorized by PPI use, identifying 903 PPI non users and 35 users. After adjusting for age, male PPI users (107.0 ± 69.6 vs. 127.1 ± 55.8, p<0.001) and female PPI users (87.6 ± 29.1 vs. 107.6 ± 52.3, p=0.03) had lower IGF-1 levels than non-users. IGFBP-1 levels were similar in the two groups in both sexes. In whole population, after adjustment for age and sex, PPI users had lower IGF-1 levels 81.9 [61.1-113.8] than non-users 110 [77.8-148.6], p=0.02. After further adjustment for BMI, albumin, liver function, C-reactive protein, Interleukin-6, number of medications, ACE-inhibitors use, caloric intake, protein intake, physical activity, glycemia, and IGFBP-1, the use of PPIs remained significantly and negatively associated with IGF-1 levels (β±SE = -19.60±9.83, p=0.045).
  
  
  CONCLUSIONS
  Use of PPIs was independently and negatively associated with IGF-1 levels.
authors.affiliation: M. Maggio, MD, PhD, Department of Clinical and Experimental Medicine, Geriatric Clinic, Food Sciences Unit and Endocrinology of Aging Unit, via Gramsci 14, 43100, Parma, Italy. Phone: 0039-0521-703916 E-Mail: marcellomaggio2001@yahoo.it.
authors.forename: M
authors.initials: M
authors.lastname: Maggio
authors.forename: F
authors.initials: F
authors.lastname: Lauretani
authors.forename: F
authors.initials: F
authors.lastname: De Vita
authors.forename: V
authors.initials: V
authors.lastname: Buttò
authors.forename: C
authors.initials: C
authors.lastname: Cattabiani
authors.forename: S
authors.initials: S
authors.lastname: Masoni
authors.forename: E
authors.initials: E
authors.lastname: Sutti
authors.forename: G
authors.initials: G
authors.lastname: Bondi
authors.forename: E
authors.initials: E
authors.lastname: Dall'aglio
authors.forename: S
authors.initials: S
authors.lastname: Bandinelli
authors.forename: A
authors.initials: A
authors.lastname: Corsonello
authors.forename: A M
authors.initials: AM
authors.lastname: Abbatecola
authors.forename: F
authors.initials: F
authors.lastname: Lattanzio
authors.forename: L
authors.initials: L
authors.lastname: Ferrucci
authors.forename: G P
authors.initials: GP
authors.lastname: Ceda
mesh_terms: D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage; D001786:Blood Glucose; D002097:C-Reactive Protein / Q000378:metabolism; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D018970:Insulin-Like Growth Factor Binding Protein 1 / Q000032:analysis / Q000378:metabolism; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000378:metabolism; D007334:Insulin-Like Growth Factor I / Q000032:analysis / Q000378:metabolism*; D015850:Interleukin-6 / Q000378:metabolism; D008297:Male; D054328:Proton Pump Inhibitors / Q000008:administration & dosage* / Q000494:pharmacology*
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D001786:Blood Glucose; D018970:Insulin-Like Growth Factor Binding Protein 1; D018972:Insulin-Like Growth Factor Binding Protein 3; D015850:Interleukin-6; D054328:Proton Pump Inhibitors; D007334:Insulin-Like Growth Factor I; D002097:C-Reactive Protein